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RTable 1Men (n[320) Women (n[230) p-valueAge (years) 69.9 [62.25-78.0] 73.33 [66.0-80.25] 0.35Race (%) <0.001White 70.3 46.4Black 7.2 23.0Hispanic 19.7 26.3Asian 0.6 1.4Other 2.2 2.9Body mass index (kg/m2) 28.2 [25.0-27.4] 28.4 [27.4-30.5] 0.89Medical history (%)Diabetes mellitus 51.6 53.3 0.64Hypertension 83.7 89.0 0.004Hyperlipidemia 80.0 84.3 0.16Coronary artery disease 64.0 50.0 0.002Prior peripheral artery revascularization 24.1 24.3 1.00Tobacco use 27.4 11.8 <0.001Medication use (%)Aspirin 57.5 49.5 0.60Clopidogrel 51.9 45.7 0.84Cilostazol 11.6 5.7 0.06Statin 63.4 53.8 0.43Insulin 17.8 12.9 0.81Laboratory dataWhite blood cell count (x 103 cells/mL) 7.7 [6.2-8.9] 10.3 [6.0-9.1] 0.99Neutrophil/lymphocyte ratio 2.86 [1.65-3.50] 1.97 [1.65-3.53] 0.70Platelet count (x 103 cells/uL) 214 [170-250] 259 [192-309] <0.001Creatinine (mg/dL) 1.38 [0.90-1.30] 1.17 [0.71-1.60] <0.001LDL-cholesterol (mg/dL) 86 [62-104] 92 [64-116] 0.14HDL-cholesterol (mg/dL) 46 [36-53] 55 [44-78] <0.001Triglycerides (mg/dL) 149 [92-187] 130 [81-200] 0.015Glucose (mg/dL) 132 [90-149] 129 [89-149] 0.99Resting ankle-brachial index (ABI)Right 0.75 [0.69-0.98] 0.67 [0.41-0.97] 0.10Left 0.79 [0.65-1.03] 0.56 [0.59-0.99] 0.07Critical limb ischemia with ABI <0.4 (%) 42.8 42.4 0.93Continuous data are presented as median [interquartile range]
Table 2Men (n[320) Women (n[230) p-valueExtent of disease (%) 0.74Mild or moderate disease 12.5 10.5Isolated severe suprapopliteal disease 31.3 32.4Isolated severe infrapopliteal disease 15.6 13.3Severe multilevel disease 40.6 43.8Men (n¼243) Women (n¼168)
Type of procedural intervention (%)Stent placement 59.3 54.8 0.42Use of adjunctive device therapy
(e.g. atherectomy, re-entry device)33.3 36.9 0.46Target vessel revascularization (%) 11.9 16.3 0.16CRT-308
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BACKGROUND The JetStream Navitus (JS) atherectomy device is a rotational cutter
with aspiration capability designed to treat infrainguinal arterial obstructive disease.
JS XC can be operated with blades down (BD) (2.1 or 2.4 mm perimeter) or blades up
(BU) (3.0 or 3.4 mm perimeter) to treat femoropopliteal obstructive disease. It is
unclear whether an orbital effect is present while operating the JS leading to a largerminimal luminal area (MLA) than predicted based on device size. Also, the minimum
MLA and plaque surface area (PSA) needed in a typical size femoral artery (5-6 mm)
for the device to be effective has not been deﬁned. Using an in-stent restenosis (ISR)
porcine model and intravascular ultrasound (IVUS) assessment of lesions these
questions were addressed.
METHOD 4 pigs (8 limbs) were implanted with overlapping SMART (Cordis) nitinol
self-expanding stents using an overstretch balloon/stent model. ISR was treated 1
month after stent implantation with an initial 2 blades down (BD) runs followed by
4 BU runs. IVUS measurements were performed at baseline, after 2 BD runs, and
after each BU run on a total of 24 lesions. Minimal luminal area (MLA, mm2) and
plaque surface area (PSA, %) were obtained. 1-sample Wilcoxon signed-rank test
was performed between MLA obtained after BU runs and theoretical maximal MLA
of the XC 2.4-3.4 cutter with BU. MLA and PSA at baseline were plotted against net
MLA and PSA gain (BU - baseline) respectively. The minimum MLA and PSA at
baseline needed for a positive increase in MLA and reduction in PSA were
determined.
RESULTS The femoral artery mean diameter was 4.7 mm. A strong correlation was
present between MLA at baseline and after BU runs (Pearson correlation p¼0.006) and
between PSA at baseline and after BU runs (p<0.0001). An approximateMLA9.0mm2
or PSA  60% were needed to see a positive effect of atherectomy on treated lesion
(i.e. increase in MLA or reduction in PSA). Theoretical MLA achievable from the XC
BU 2.4-3.4 device is 9.08 mm2 (A ¼ pr2 using r¼3.4/2¼1.7mm). No difference is
seen between this calculated MLA and the IVUS measured MLAs after BU
runs using 1-sample Wilcoxon test indicating no orbital effect of the device on tissue
cutting.
CONCLUSION JS XC 2.4-3.4 BU achieved positive cutting of ISR tissue inside a 4.7 mm
femoral artery when the baseline lesion MLA was  9.0 mm2 or PSA  60% on IVUS.
No orbital cutting was seen with the JS BU as MLA obtained after treatment was not
different from theoretical MLA.CRT-309
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BACKGROUND Recently, it was reported that statins are associated with lower rates
of major adverse cardiovascular events and amputations in critical limb ischemia
(CLI) patients (pts). However, the impact of statin administration duration on clinical
outcomes for pts undergoing percutaneous transluminal angioplasty (PTA) due to
peripheral arterial disease (PAD) is uncertain.
METHODS A total 286 pts underwent PTA for PAD from Oct 2004 to Feb 2013 from
prospective PTA registry was enrolled. Major adverse cardiovascular and extremity
events (MACEEs) were deﬁned as the composite end-point consisted of cardiac death,
myocardial infarction, repeat PTA, and amputation. The incidence of MACEEs ac-
cording to statin duration up to 1-year was evaluated.
RESULTS The incidences of total MACEEs was in 33.2% (95/286 pts); cardiac death 7
(2.4%), myocardial infarction 3 (1.0%), major and minor amputation 56 (19.6%), repeat
PTA 46 (16.1%). Not only the univariate logistic regression analysis, but also in
multivariate logistic regression adjusted by age, gender, hypertension, diabetes, ce-
rebrovascular accident, and chronic renal failure, there was signiﬁcant risk reduction
for MACEES in statin use duration 180 and 360 days group, not in statin use duration
30 and 90 days (Table).
CONCLUSIONS In our study, prolonged statin duration at least longer than 6 months
was associated with reduced risk of MACEES compared with shorter statin duration in
pts undergoing PTA for PAD.
